Loading…
French maker of in-vitro diagnostics instruments and reagents for clinical microbiology and infectious disease testing.
French maker of in-vitro diagnostics instruments and reagents for clinical microbiology and infectious disease testing.
Places instruments in hospital and industrial labs, then earns on the tests run on them, so installed instruments drive repeat sales of reagents. Its 2014 purchase of BioFire added panels that test for many pathogens at once and made the US a main market. The Merieux family, through Institut Merieux, controls it.
Moat: narrow (installed base, switching costs, IP / patents). Placed diagnostic instrument base creates recurring reagent/consumable revenue.
Headquarters: Marcy-l'Etoile, France · Founded: 1963 · Employees: 15,078
Size bioMerieux (BIM.PA) is a France Health Care company (Medical Specialties) with a market value of $12.4B, the 42nd largest of 206 France companies the cockpit tracks. Shares closed at €93.30 on 6 Nov 2026.
Performance Over six months the shares gained 28.8%, against +32.5% for the median peer and -0.4% for the France market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 3.2% over the last twelve months (peer median +5.0%); the operating margin is 15.2% (peer median 14.3%).
Valuation It trades at 20.9× forward earnings against a peer median of 19.9× (10th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.7 points above its cost of capital (8.4% WACC).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €3.99B | €4.07B | €3.98B | €3.67B | €3.59B |
| Revenue growth | — | +2% | +8% | +2% | — |
| Gross profit | €2.21B | €2.27B | €2.18B | €2.02B | €1.96B |
| EBITDA | €919M | €973M | €893M | €795M | €817M |
| Net income | €463M | €398M | €432M | €358M | €452M |
| Free cash flow | €586M | €453M | €322M | €107M | €188M |
| Capital expenditure | €322M | €335M | €346M | €338M | €287M |
| Total debt | n/a | €461M | €491M | €519M | €505M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| bioMerieux BIM.PA | $12.4B | +29% | -3% | 15% | 20.9× | 8.9% |
| Abbott Laboratories ABT | $190B | +30% | +10% | 14% | 18.8× | 5.6% |
| Becton Dickinson BDX | $57.7B | +43% | -3% | 15% | 16.0× | 9.6% |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 25.8× | 20.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BIM.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.0% | +8.4% | 5th highest of 21 |
| 6-month return | +28.8% | +32.5% | 11th highest of 21 |
| Distance from 52-week high | -19.6% | -12.5% | 6th lowest of 21 |
| Revenue growth (TTM) | -3.2% | +5.0% | lowest of 21 |
| Operating margin | 15.2% | 14.3% | 11th highest of 21 |
| Forward P/E | 20.9× | 19.9× | 10th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 8.9% | 10.7% | 8th least demanding of 19 |
| Growth delivered (Del g) | +5.5% | +9.0% | 6th lowest of 19 |
| Hurdle (Req g minus delivered) | +3.4 pp | +3.3 pp | 10th least demanding of 19 |
| ROIC minus cost of capital | +2.7 pp | +2.4 pp | 10th highest of 21 |
| EV / EBITDA | 11.7× | 14.2× | 6th cheapest of 18 |
| Net debt / EBITDA | -0.3× | 1.2× | 5th least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| bioMerieux BIM.PA | France | $12.4B | +29% | -3% | 15% | 20.9× | 8.9% | +5.5% |
| Olympus 7733.T | Japan | $12.2B | +13% | +8% | 16% | 18.0× | -1.5% | +6.7% |
| Penumbra PEN | United States | $12.6B | -1% | +17% | 12% | 54.9× | 30.1% | +20.2% |
| Cooper Companies (The) COO | United States | $11.9B | +4% | +5% | 19% | 13.8× | 9.4% | +11.0% |
| Align Technology ALGN | United States | $11.8B | -2% | +4% | 19% | 13.9× | 11.4% | +10.3% |
| Smith & Nephew SN..L | United Kingdom | $13.1B | +5% | +2% | 17% | 14.4× | 11.1% | +5.6% |
| Demant A/S DEMANT.CO | Denmark | $11.6B | +62% | +10% | 18% | 25.7× | 6.8% | +9.8% |
| Glaukos GKOS | United States | $13.3B | +68% | +47% | -9% | 155.4× | n/a | n/a |
| Baxter International BAX | United States | $13.3B | +43% | +5% | 6% | 12.6× | 12.7% | -0.7% |
| Lenskart Solutions LENSKART.NS | India | $13.4B | +49% | +35% | 10% | 137.4× | 52.8% | +33.5% |
| Avantor AVTR | United States | $10.5B | +86% | +1% | 8% | 17.7× | 16.1% | +0.5% |
| Qiagen QGEN | United States | $10.4B | +52% | +3% | 25% | 19.8× | 8.8% | +2.2% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.8B | +9% | +27% | 9% | 46.9× | n/a | n/a |
| Bio-Rad Laboratories BIO | United States | $10.3B | +50% | +1% | 9% | 35.7× | 26.5% | +0.3% |
| Insulet PODD | United States | $10.2B | -5% | +26% | 18% | 19.5× | 10.3% | +24.5% |
| Globus Medical GMED | United States | $9.54B | -9% | +20% | 22% | 14.1× | 5.5% | +30.1% |
| Bruker BRKR | United States | $9.34B | +39% | +2% | 9% | 26.2× | 25.7% | +11.6% |
| Revvity RVTY | United States | $17.3B | +54% | +5% | 15% | 26.7× | 27.3% | -5.5% |
| Coloplast A/S COLO-B.CO | Denmark | $17.7B | +26% | +4% | 25% | 19.9× | -1.8% | +8.3% |
| Sysmex 6869.T | Japan | $7.89B | +50% | +4% | 13% | 31.2× | 4.4% | +10.4% |
| Shimadzu 7701.T | Japan | $7.79B | +15% | +6% | 13% | 19.5× | 6.3% | +7.3% |